Schroder Investment Management Group
NTLA icon

Schroder Investment Management Group’s Intellia Therapeutics NTLA Stock Holding History

Schroder Investment Management Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-406,425
Closed -$3.81M – 1240
2025
Q2 		$3.81M Buy
406,425
+382,425
+1,593% +$3.14M ﹤0.01% 819
2025
Q1 		$194K Hold
24,000
– – ﹤0.01% 1163
2024
Q4 		$274K Sell
24,000
-61,999
-72% -$968K ﹤0.01% 1152
2024
Q3 		$1.81M Sell
85,999
-485
-0.6% -$11.2K ﹤0.01% 953
2024
Q2 		$1.94M Sell
86,484
-441
-0.5% -$10.5K ﹤0.01% 934
2024
Q1 		$2.39M Sell
86,925
-1,577
-2% -$43.8K ﹤0.01% 897
2023
Q4 		$2.7M Sell
88,502
-41,197
-32% -$1.18M ﹤0.01% 866
2023
Q3 		$4.1M Sell
129,699
-12,473
-9% -$484K 0.01% 787
2023
Q2 		$5.8M Sell
142,172
-22,131
-13% -$897K 0.01% 758
2023
Q1 		$6.12M Buy
164,303
+56,689
+53% +$2.22M 0.01% 738
2022
Q4 		$3.75M Buy
107,614
+23,754
+28% +$1.13M 0.01% 829
2022
Q3 		$4.69M Sell
83,860
-7,631
-8% -$473K 0.01% 784
2022
Q2 		$4.8M Buy
91,491
+1,744
+2% +$88.6K 0.01% 795
2022
Q1 		$6.48M Buy
+89,747
New +$7.6M 0.01% 776

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group's NTLA Position: Q3 2025 in Review

Schroder Investment Management Group sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 406,425 shares — an estimated $3.81M sold.

Schroder Investment Management Group first reported a position in NTLA in Q1 2022 and held it in 14 quarters. The position peaked at $6.48M in Q1 2022. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Schroder Investment Management Group reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 406,425 Intellia Therapeutics shares in Q3 2025, an estimated $3.81M.
  • Schroder Investment Management Group first reported a position in Intellia Therapeutics in Q1 2022 and held it in 14 quarters.
  • Schroder Investment Management Group's Intellia Therapeutics position peaked at $6.48M in Q1 2022.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Schroder Investment Management Group's 13F filing for Q3 2025, filed 13 Nov 2025.